Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23297284 | 0.79 | MEN1 (0.60) | PDE4APDE4BPDE4CPDE4DHDAC1 | |
| SCHEMBL23297262 | 0.78 | PGR (0.52) | PGRPDE3BPDE3APDE4APDE4B | |
| SCHEMBL1900155 | 0.76 | AHR (0.77) | AHRPGRPDE3BPDE3APDE4A | |
| SCHEMBL29776794 | 0.76 | GSK3B (0.47) | PDE4APDE4BPDE4CPDE4DHDAC1 | |
| SCHEMBL23297223 | 0.76 | GSK3B (0.47) | PDE4APDE4BPDE4CPDE4DHDAC1 | |
| SCHEMBL29776812 | 0.75 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4DHDAC1 | |
| SCHEMBL23297281 | 0.75 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4DHDAC1 | |
| SCHEMBL29776790 | 0.74 | PDE4A (0.45) | PDE4APDE4BPDE4CPDE4DHDAC1 | |
| SCHEMBL29776820 | 0.74 | PDE4A (0.45) | PDE4APDE4BPDE4CPDE4DHDAC1 | |
| SCHEMBL29776821 | 0.74 | PDE4A (0.45) | PDE4APDE4BPDE4CPDE4DHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240833-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-3877367-B1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20230338375-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230338375-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230048816-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| US-11390606-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPECUTICS, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| WO-2021231630-A1 | SUBSTITUTED PYRIDAZINONE FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| US-20210130327-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-05-06 | — | — | US | disclosed |
| US-20210130327-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338375-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, MUSK, SMN1; SMN2 | AHR 2690/4885PGR 914/4885PDE3B 187/4885 |
| US-12240833-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | AHR 2582/4885PGR 869/4885PDE3B 179/4885 |
| US-11390606-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | AHR 2582/4885PGR 869/4885PDE3B 179/4885 |
| US-20210130327-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | AHR 2582/4885PGR 869/4885PDE3B 179/4885 |
| US-20230048816-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | AHR 2582/4885PGR 869/4885PDE3B 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.